iMDK (CAS No 881970-80-5) is a promising compound in the field of biomedical research particularly known for its potential in oncology studies Originating from extensive research efforts to identify effective anti-cancer agents iMDK functions primarily by targeting specific signaling pathways involved in cell proliferation and apoptosis such as the MAPK/ERK pathway It is known to exhibit potent in vitro activity in the nanomolar to low micromolar range making it an attractive candidate for laboratory investigations Frequently utilized in various cellular models and animal studies iMDK helps to elucidate mechanisms of tumor growth and explores potential therapeutic interventions Its role in high-throughput drug screening further highlights its importance in the discovery of novel cancer treatments Experimental concentrations typically depend on the specific research design offering flexibility in diverse experimental setups to assess its effectiveness and safety profiles